Celecoxib for preterm birth

Celecoxib for preterm birth - Celecoxib for preterm birth

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026304

Enrollment

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preterm birth

Interventions

The administration of Celecoxib (200mg/day) Until the symptoms disapear or 27 weeks of gestation

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The patients of preterm birth with symptoms of low abdominal pain or uterine contraction between 10 to 27 weeks gestation, and those agree with the enrollment to this study.

Exclusion criteria

Exclusion criteria: The patients who do not agree with the enrollment to this study.

Design outcomes

Primary

Measure	Time frame
gestational age, amniotic fluid volume, peak systolic velocity of ductus arteriosus	—

Countries

Japan

Contacts

Public ContactYoshitsugu Chigusa

The Kyoto University Hospital Department of Gynecology and Obstetrics

chigusa@kuhp.kyoto-u.ac.jp075-751-3269

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026